N-Methyl-undecansaeure-amid | 6212-94-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-Methyl-undecansaeure-amid
• 英文别名: N-methyl-undecanamide；Undecansaeure-methylamid；Undecylsaeure-methylamid；N-Methyl-undecanamid；2-azatridecanone；N-methylundecamide；N-methylundecanamide
• CAS: 6212-94-8
• 化学式: C₁₂H₂₅NO
• mdl: MFCD24390891
• 分子量: 199.337
• InChiKey: MUZVJRFZJAXVBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.916
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-Methyl-undecansaeure-amid 、 1-(biphenyl-4-yl)ethanamine hydrochloride 在 盐酸 、 三氯氧磷 作用下， 以 苯 为溶剂， 生成 2-[α-(4-Biphenylyl)ethylimino]azacyclotridecane hydrochloride
  参考文献：
  名称：

  Lactamimide inhibitors of gastrointestinal hypersecretion

  摘要：

  治疗胃肠道高分泌的方法，包括给予替代的内酰胺衍生物。

  公开号：

  US04061746A1
• 作为产物：
  描述：

  N,N-二甲基十一烷酰胺 在 [ruthenium(II)(η⁶-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]₂ 、 正丁醇 作用下， 反应 10.0h， 生成 N-Methyl-undecansaeure-amid
  参考文献：
  名称：

  一种制备一级和二级酰胺化合物的方法

  摘要：

  本发明属于有机化学合成领域，具体涉及一种制备一级和二级酰胺化合物的方法。一种制备一级和二级酰胺化合物的方法，以质子性溶剂为还原试剂，以二氯(对甲基异丙苯)钌(II)二聚体配合物为催化剂，在30℃～130℃温度下催化还原N‑取代酰胺化合物，还原反应结束后得到反应液，对反应液进行后处理即得到相应的一级酰胺化合物或二级酰胺化合物。本发明公开的一种制备一级和二级酰胺化合物的方法实现了氮‑氧和氮‑碳键的转移氢化反应，反应条件温和简单，底物适用范围广，操作方便，高效高选择性的得到相应的一级酰胺化合物或二级酰胺化合物。

  公开号：

  CN112321449A

文献信息

• NOVEL 1,3-BENZOXAZOL-2(3H)-ONES AND THEIR USE AS MEDICAMENTS AND COSMETICS
  申请人：DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL

  公开号：US20150111935A1

  公开（公告）日：2015-04-23

  The present invention relates to a novel class of 1,3-benzoxazol-2(3H)-ones and their use as a medicament, preferably as a dermatologic agent, and as a cosmetic. These novel compounds are particularly useful in treating and/or preventing inflammation, irritation, itching, pruritus, pain, oedema and/or pro-allergic or allergic conditions in a patient. Usually they are topically applied to the skin or mucosa in the form of a pharmaceutical or cosmetic composition comprising the compound and a pharmaceutically and/or cosmetically acceptable carrier.

  本发明涉及一种新型的1,3-苯并噁唑-2(3H)-酮类化合物及其作为药物的用途，尤其是作为皮肤科药剂和化妆品的用途。这些新型化合物在治疗和/或预防患者的炎症、刺激、瘙痒、瘙痒、疼痛、水肿和/或过敏症状方面特别有用。通常它们以药用或化妆品组合物的形式局部应用于皮肤或黏膜，包括该化合物和一种药学和/或化妆学可接受的载体。
• COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS
  申请人：ARDELYX, INC.

  公开号：US20150299131A1

  公开（公告）日：2015-10-22

  The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

  本公开涉及化合物和治疗液体潴留或盐过多症状的方法，如心力衰竭（特别是充血性心力衰竭）、慢性肾脏疾病、末期肾脏疾病、肝病和过氧化物酶体增殖物激活受体（PPAR）γ激动剂引起的液体潴留。本公开还涉及化合物和治疗高血压的方法。本公开还涉及化合物和治疗胃肠道疾病的方法，包括治疗或减轻与胃肠道疾病相关的疼痛。
• 4-ACYLAMINOPYRAZOLE DERIVATIVES
  申请人：Sankyo Company, Limited

  公开号：EP1329160A2

  公开（公告）日：2003-07-23

  A 4-acylaminopyrazole derivative represented by the following general formula: wherein R1 is a hydrogen atom, an optionally substituted C1-C16 alkyl group or the like,    R2 and R3 are independently a hydrogen atom, a halogen atom, an optionally substituted C1-C6 alkyl group or the like, R4 is a hydrogen atom, a C1-C6 alkyl group or a cyano group, Z is an oxygen atom or a sulfur atom, Ar is an optionally substituted C6-C14 aryl group or an optionally substituted 5-6 membered unsaturated heterocyclic group, B is a hydrogen atom, a halogen atom, an optionally substituted C1-C16 alkyl group or the like.

  由以下通式代表的 4-酰氨基吡唑衍生物： 其中 R1 是氢原子、任选取代的 C1-C16 烷基或类似基团、 R2 和 R3 独立地为氢原子、卤素原子、任选取代的 C1-C6 烷基或类似基团、 R4 是氢原子、C1-C6 烷基或氰基、 Z 是氧原子或硫原子、 Ar 是任选取代的 C6-C14 芳基或任选取代的 5-6 位元不饱和杂环基团、 B 是氢原子、卤素原子、任选取代的 C1-C16 烷基或类似基团。
• Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
  申请人：Ardelyx, Inc.

  公开号：US10385024B2

  公开（公告）日：2019-08-20

  The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

  本公开内容涉及用于治疗与体液潴留或盐负荷过重相关的疾病的化合物和方法，如心力衰竭（尤其是充血性心力衰竭）、慢性肾病、终末期肾病、肝病和过氧化物酶体增殖激活受体（PPAR）γ激动剂诱导的体液潴留。本公开还涉及治疗高血压的化合物和方法。本公开还涉及治疗胃肠道疾病的化合物和方法，包括治疗或减轻与胃肠道疾病相关的疼痛。
• Compositions comprising non-halogenated solvents for use in oil and/or gas wells and related methods
  申请人：Flotek Chemistry, LLC

  公开号：US10934472B2

  公开（公告）日：2021-03-02

  Compositions comprising non-halogenated solvents for use in various aspects of a life cycle of an oil and/or gas well, and related methods, are provided. In some embodiments, the composition comprises a solvent blend and one or more surfactants. In some embodiments, the solvent blend comprises a first type of solvent (e.g., a terpene) and a second type of solvent (e.g., a non-halogenated solvent). The composition may comprise about 90 wt % to 99.9 wt % of the solvent blend, and about 0.1 wt % to 10 wt % of one or more surfactants, versus the total weight of the composition. In some embodiments, compositions can be used in methods for treating an oil and/or gas well, having a wellbore that comprises one or more fluids. A composition may be delivered into the wellbore, passing through the one or more fluids to reduce residues comprising asphaltenes, paraffins or combinations thereof on or near the wellbore.

  本文提供了包含非卤化溶剂的组合物，用于油井和/或气井生命周期的各个方面，并提供了相关方法。在某些实施方案中，组合物包括混合溶剂和一种或多种表面活性剂。在某些实施方案中，混合溶剂包括第一类溶剂（如萜烯）和第二类溶剂（如无卤溶剂）。相对于组合物的总重量，组合物可包含约 90 重量份至 99.9 重量份的混合溶剂，以及约 0.1 重量份至 10 重量份的一种或多种表面活性剂。在某些实施方案中，组合物可用于处理油井和/或气井的方法，该油井有一个包含一种或多种流体的井筒。可将组合物输送到井筒中，通过一种或多种流体，以减少井筒上或附近由沥青质、石蜡或其组合组成的残留物。